By Silas Inman
Eisai has submitted a New Drug Application for lenvatinib (E7080) as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), based on findings from the phase III SELECT trial that was presented at the 2014 ASCO Annual Meeting.
By Andrew J. Roth
Robert Petit, PhD, the chief scientific officer at Advaxis, provides insight into the ADXS-PSA immunotherapy and the rationale behind the combination study with pembrolizumab.
By Arnold Etame, MD, PhD
Immunotherapy is rapidly emerging as a very attractive and novel therapeutic approach for cancer, including for glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults.
For patients with cancer, factors associated with late admission to hospice have been identified, according to a study published online Aug. 25 in the Journal of Clinical Oncology.
Children with newly diagnosed leukemia with an index admission on the weekend have an increased length of stay and risk for respiratory failure, according to a study published online Aug. 25 in JAMA Pediatrics.
By Beth Fand Incollingo
It took just a minute and a half for a disgruntled patient to leave his deadly mark on a Nevada urology clinic, irreversibly changing the lives of everyone inside.
By Amy Jacob
A new multi-step skin testing protocol effectively determines the presence of isosulfan blue allergy, according to a study conducted by researchers at the University of Virginia.
For the second year running, physician turnover remains at the highest rate since 2005, according to a report published by the American Medical Group Association.
For physicians trying to balance various financial and time pressures, ethical dilemmas are common, according to an article published Aug. 7 in Medical Economics.
By Sagar B. Kudchodkar, PhD, and Marcela V. Maus, MD, PhD
Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy in which the patient’s own T cells are isolated in the laboratory, redirected with a synthetic receptor to recognize a particular antigen or protein, and reinfused into the patient.
By Adam Hochron
As the practice of telecare continues to gain momentum, a group of researchers conducted a study to test how effective that course of treatment is in patients with chronic illnesses.
By Andrew L. Pecora, MD
There is a growing chorus that seems to be debating separate issues—340B drug pricing, the sequester, site of service differential, etc. But the debate revolves around a singular issue—where should cancer care be delivered?
Patients with cancer and depression frequently do not receive effective treatment; however, an integrated program is effective in patients with cancer, and specifically lung cancer, according to three studies published online Aug. 28 in The Lancet Psychiatry, The Lancet, and The Lancet Oncology.
Treatment-naive patients with multiple myeloma frequently have sensory deficits, according to a study published online Aug. 25 in the Journal of Clinical Oncology.
Patients with polycythemia vera can be classified according to disease behavior, independently of Janus kinase 2 V617F allele burden, after removing sex as a potential confounder, according to a study published in the Aug. 28 issue of the New England Journal of Medicine.
Focal liver lesions are mostly benign, and can be diagnosed based on knowledge of their presentation, associated clinical and laboratory features, and natural history, according to clinical guidelines published online Aug. 19 in the American Journal of Gastroenterology.
By Beth Fand Incollingo
Sipuleucel-T (Provenge) is effective when given either before or after androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer (BRPC) who face a high risk of developing metastases, a study has found.
By Tony Berberabe, MPH
Although advances in endocrine therapy for women with estrogen receptor (ER)-positive breast cancer have been made in recent years, de novo and acquired resistance to treatments remain important clinical problems, and efforts to identify effective modalities to overcome this challenge continue.
By Andrew J. Roth
Advaxis and Merck have entered into a clinical trial collaboration agreement to evaluate the combination of two novel immunotherapies for the treatment of patients with metastatic castration-resistant prostate cancer.
By Arjun Vasant Balar, MD
A major step toward improved tolerability of cisplatin-based therapy came in the early 2000s with the advent of the modern regimen of gemcitabine and cisplatin.